{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:30:59Z","timestamp":1789497059404,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omtn.2025.102776","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:58:12Z","timestamp":1763639892000},"page":"102776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of exosomes as oligonucleotide delivery system for managing \u03b1-synuclein in Parkinson\u2019s disease: A systematic review of in vivo studies"],"prefix":"10.1016","volume":"36","author":[{"given":"Soodeh","family":"Salarpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Dourandish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan","family":"Salajegheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5944-6432","authenticated-orcid":false,"given":"Sara","family":"Hashemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2025.102776_bib1","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2025.102776_bib2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.2019.22360","article-title":"Diagnosis and treatment of Parkinson disease: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.omtn.2025.102776_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41582-024-01034-x","article-title":"Parkinson disease therapy: current strategies and future research priorities","volume":"20","author":"Stocchi","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtn.2025.102776_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.mocell.2025.100274","article-title":"Current Therapeutic Strategies in Parkinson\u2019s Disease: Future Perspectives","volume":"48","author":"Kim","year":"2025","journal-title":"Mol. Cells"},{"key":"10.1016\/j.omtn.2025.102776_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41531-021-00203-9","article-title":"Alpha-synuclein research: defining strategic moves in the battle against Parkinson\u2019s disease","volume":"7","author":"Oliveira","year":"2021","journal-title":"npj Parkinson's Dis."},{"key":"10.1016\/j.omtn.2025.102776_bib6","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.3390\/ijms25179197","article-title":"The role of \u03b1-synuclein in etiology of neurodegenerative diseases","volume":"25","author":"Krawczuk","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2025.102776_bib7","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.3390\/cells11111732","article-title":"Alpha-synuclein aggregation pathway in Parkinson\u2019s disease: current status and novel therapeutic approaches","volume":"11","author":"Vidovi\u0107","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omtn.2025.102776_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13024-023-00675-8","article-title":"Peptide-based approaches to directly target alpha-synuclein in Parkinson\u2019s disease","volume":"18","author":"Allen","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.omtn.2025.102776_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4062\/biomolther.2025.022","article-title":"RNA Therapeutics: Focus on Antisense Oligonucleotides in the Nervous System","volume":"33","author":"Ertural","year":"2025","journal-title":"Biomol. Ther."},{"key":"10.1016\/j.omtn.2025.102776_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/ejn.70110","article-title":"RNA-Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins","volume":"61","author":"Rabbani","year":"2025","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.omtn.2025.102776_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1034072","article-title":"miRNA and antisense oligonucleotide-based \u03b1-synuclein targeting as disease-modifying therapeutics in Parkinson\u2019s disease","volume":"13","author":"Suvarna","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.omtn.2025.102776_bib12","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.3390\/pharmaceutics14122652","article-title":"Extracellular vesicle-based therapeutics in neurological disorders","volume":"14","author":"Yuan","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102776_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s13346-021-01026-0","article-title":"Exosomes as cell-derivative carriers in the diagnosis and treatment of central nervous system diseases","volume":"12","author":"Shetgaonkar","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.omtn.2025.102776_bib14","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1038\/s41467-023-40453-0","article-title":"Identification of scaffold proteins for improved endogenous engineering of extracellular vesicles","volume":"14","author":"Zheng","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtn.2025.102776_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12951-025-03352-8","article-title":"Exosome-powered neuropharmaceutics: unlocking the blood-brain barrier for next-gen therapies","volume":"23","author":"Mehdizadeh","year":"2025","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102776_bib16","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.2147\/IJN.S464249","article-title":"Engineering exosomes for therapeutic applications: decoding biogenesis, content modification, and cargo loading strategies","volume":"19","author":"Bahadorani","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.omtn.2025.102776_bib17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/biomedicines11041231","article-title":"Bioengineered mesenchymal-stromal-cell-derived extracellular vesicles as an improved drug delivery system: methods and applications","volume":"11","author":"Ulpiano","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102776_bib18","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1002\/mds.25978","article-title":"Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice","volume":"29","author":"Cooper","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.omtn.2025.102776_bib19","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.ymthe.2019.08.010","article-title":"Systemic exosomal delivery of shRNA minicircles prevents parkinsonian pathology","volume":"27","author":"Izco","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2025.102776_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105218","article-title":"Exosome-mediated delivery of antisense oligonucleotides targeting \u03b1-synuclein ameliorates the pathology in a mouse model of Parkinson's disease","volume":"148","author":"Yang","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.omtn.2025.102776_bib21","doi-asserted-by":"crossref","first-page":"eaba3967","DOI":"10.1126\/sciadv.aba3967","article-title":"Targeted exosome coating gene-chem nanocomplex as \u201cnanoscavenger\u201d for clearing \u03b1-synuclein and immune activation of Parkinson\u2019s disease","volume":"6","author":"Liu","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102776_bib22","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.omtn.2019.07.008","article-title":"Exosomal DNA aptamer targeting \u03b1-synuclein aggregates reduced neuropathological deficits in a mouse Parkinson\u2019s disease model","volume":"17","author":"Ren","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102776_bib23","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/S1353-8020(11)70057-8","article-title":"Animal models of Parkinson's disease","volume":"18","author":"Jackson-Lewis","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.omtn.2025.102776_bib24","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","article-title":"Animal models of \u03b1-synucleinopathy for Parkinson disease drug development","volume":"18","author":"Koprich","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.omtn.2025.102776_bib25","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3233\/JPD-202200","article-title":"Animal models of Parkinson\u2019s disease: are they useful or not?","volume":"10","author":"Barker","year":"2020","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.omtn.2025.102776_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s12967-021-02980-6","article-title":"A paradigm shift in cell-free approach: the emerging role of MSCs-derived exosomes in regenerative medicine","volume":"19","author":"Moghadasi","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.omtn.2025.102776_bib27","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-021-00736-4","article-title":"New therapeutic approaches of mesenchymal stem cells-derived exosomes","volume":"28","author":"Janockova","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.omtn.2025.102776_bib28","article-title":"Evaluating the Safety and Efficacy of MSCs-derived Exosomes for Treatment of Resistant Perianal Fistula in IBD patients; Clinical Trial Phase I","volume":"10","author":"Nazari","year":"2022","journal-title":"Gastroenterol. Rep. (Oxf)"},{"key":"10.1016\/j.omtn.2025.102776_bib29","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.omtn.2021.01.022","article-title":"Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson\u2019s disease","volume":"23","author":"Li","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2025.102776_bib30","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12951-022-01472-z","article-title":"Recent advances in exosome-mediated nucleic acid delivery for cancer therapy","volume":"20","author":"Zhang","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.omtn.2025.102776_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.impact.2020.100261","article-title":"Exosome engineering: Current progress in cargo loading and targeted delivery","volume":"20","author":"Fu","year":"2020","journal-title":"NanoImpact"},{"key":"10.1016\/j.omtn.2025.102776_bib32","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.2147\/IJN.S444582","article-title":"Engineered exosome for drug delivery: recent development and clinical applications","volume":"18","author":"Tian","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.omtn.2025.102776_bib33","doi-asserted-by":"crossref","first-page":"eabp9435","DOI":"10.1126\/sciadv.abp9435","article-title":"Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases","volume":"8","author":"Wan","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtn.2025.102776_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1444437","article-title":"Advances in delivery systems for CRISPR\/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles","volume":"15","author":"Song","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2025.102776_bib35","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","article-title":"RNA delivery by extracellular vesicles in mammalian cells and its applications","volume":"21","author":"O\u2019Brien","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.omtn.2025.102776_bib36","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40259-024-00644-7","article-title":"Splice-modulating antisense oligonucleotides as therapeutics for inherited metabolic diseases","volume":"38","author":"Chen","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.omtn.2025.102776_bib37","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1039\/D4NR00207E","article-title":"Role of aptamer technology in extracellular vesicle biology and therapeutic applications","volume":"16","author":"Chowdhury","year":"2024","journal-title":"Nanoscale"},{"key":"10.1016\/j.omtn.2025.102776_bib38","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.matt.2020.11.002","article-title":"Integrating DNA nanotechnology with aptamers for biological and biomedical applications","volume":"4","author":"Huang","year":"2021","journal-title":"Matter"},{"key":"10.1016\/j.omtn.2025.102776_bib39","doi-asserted-by":"crossref","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omtn.2025.102776_bib40","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.addr.2020.04.004","article-title":"Extracellular vesicles as drug delivery systems: Why and how?","volume":"159","author":"Elsharkasy","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102776_bib41","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1080\/03639045.2025.2541789","article-title":"Prospects of Engineered Exosomes in Clinical Applications: A Review","volume":"51","author":"Li","year":"2025","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.omtn.2025.102776_bib42","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3390\/pr9020356","article-title":"Overview and update on methods for cargo loading into extracellular vesicles","volume":"9","author":"Han","year":"2021","journal-title":"Processes"},{"key":"10.1016\/j.omtn.2025.102776_bib43","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","article-title":"siRNA functionalized lipid nanoparticles (LNPs) in management of diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.omtn.2025.102776_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.omtn.2025.102776_bib45","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.3390\/biomedicines12071523","article-title":"Recombinant Adeno-Associated Virus vectors for Gene Therapy of the Central Nervous System: delivery routes and clinical aspects","volume":"12","author":"S\u0142yk","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.omtn.2025.102776_bib46","series-title":"Genome Editing for Neurodegenerative Diseases","first-page":"135","article-title":"Transgene delivery system: viral, nonviral, and other methods for central nervous system","author":"Sahu","year":"2025"},{"key":"10.1016\/j.omtn.2025.102776_bib47","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1021\/acsomega.1c01755","article-title":"Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation","volume":"6","author":"Cui","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.omtn.2025.102776_bib48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acs.bioconjchem.9b00085","article-title":"Harnessing exosomes for the development of brain drug delivery systems","volume":"30","author":"Zheng","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omtn.2025.102776_bib49","first-page":"75","article-title":"A comprehensive overview of exosomes as drug delivery vehicles\u2014endogenous nanocarriers for targeted cancer therapy","volume":"1846","author":"Johnsen","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.omtn.2025.102776_bib50","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41565-021-00931-2","article-title":"Extracellular vesicles as a next-generation drug delivery platform","volume":"16","author":"Herrmann","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.omtn.2025.102776_bib51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.addr.2018.06.017","article-title":"Strategic design of extracellular vesicle drug delivery systems","volume":"130","author":"Armstrong","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtn.2025.102776_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.834775","article-title":"Exosomes in age-related cognitive decline: mechanistic insights and improving outcomes","volume":"14","author":"Duggan","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.omtn.2025.102776_bib53","author":"Provenzano"},{"key":"10.1016\/j.omtn.2025.102776_bib54","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.3390\/jcm11113223","article-title":"Cell-derived exosomes as therapeutic strategies and exosome-derived microRNAs as biomarkers for traumatic brain injury","volume":"11","author":"Wang","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.omtn.2025.102776_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70386","article-title":"Exosome-Based Therapeutics: A Natural Solution to Overcoming the Blood\u2013Brain Barrier in Neurodegenerative Diseases","volume":"6","author":"Sun","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.omtn.2025.102776_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253125003300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T02:08:27Z","timestamp":1766196507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253125003300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2162253125003300"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102776","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of exosomes as oligonucleotide delivery system for managing \u03b1-synuclein in Parkinson\u2019s disease: A systematic review of in vivo studies","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2025.102776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102776"}}